Jean-louis Junien
Daix, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 13, 2024
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment.
Journal: JHEP reports : innovation in hepatology
Published: September 27, 2024
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: August 03, 2024
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.
Journal: Nature communications
Published: October 12, 2023
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Journal: The New England journal of medicine
Published: October 20, 2021
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Journal: Journal of hepatology
Published: May 04, 2020
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Journal: PloS one
Published: October 31, 2019
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Journal: Journal of medicinal chemistry
Published: February 16, 2018
The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.
Journal: Hepatology communications
Published: March 17, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
Journal: Annals of the rheumatic diseases
Published: November 13, 2016
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Journal: Annals of the rheumatic diseases
Published: June 04, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026